CASSAVA SCIENCES INC. - COMMON STOCK

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

01 May 2024 09:10:00 By Nasdaq GlobeNewswire

Redemption Date Announced for Warrants

15 Apr 2024 09:20:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

25 Mar 2024 09:13:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

04 Mar 2024 09:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

28 Feb 2024 09:14:00 By Nasdaq GlobeNewswire

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

07 Feb 2024 09:08:00 By Nasdaq GlobeNewswire

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

05 Jan 2024 09:12:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

12 Dec 2023 09:13:00 By Nasdaq GlobeNewswire

Cassava Sciences Appoints Three New Members to its Board of Directors

07 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

07 Nov 2023 09:01:00 By Nasdaq GlobeNewswire

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

06 Nov 2023 09:15:00 By Nasdaq GlobeNewswire

MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)

25 Oct 2023 09:15:00 By Nasdaq GlobeNewswire

Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

12 Oct 2023 23:43:21 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY

05 Oct 2023 09:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

02 Oct 2023 09:00:44 By Nasdaq GlobeNewswire

Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease

18 Sep 2023 09:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

11 Sep 2023 09:10:00 By Nasdaq GlobeNewswire

Cassava Sciences Invited to Present in Four Upcoming Investor Conferences

06 Sep 2023 09:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

03 Aug 2023 09:07:00 By Nasdaq GlobeNewswire

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

05 Jul 2023 09:15:00 By Nasdaq GlobeNewswire